Chongqing Doptech Pharmaceutical Competitors and Similar CompaniesClear all

Chongqing Doptech Pharmaceutical's competitors and similar companies include Soiken Holdings, OXAPHARMA, Teikoku and Jumpcan Pharmaceutical.

	Chongqing Doptech Pharmaceutical Chongqing Doptech Pharmaceutical (重庆多普达药业有限公司 (also known as Doptech Pharmaceuticals)) is a distributor of drugs and pharmaceutical products.	Soiken Holdings Soiken Holdings (総医研ホールディングスにつ) is a company that researches and develops biomarkers.	OXAPHARMA OXAPHARMA is a producer of pharmaceutical and cosmetic products.	Teikoku Teikoku is a developer of pharmaceuticals.	Jumpcan Pharmaceutical Jumpcan Pharmaceutical (济川药业) is a manufacturer and distributor of chemical-based and medicine health products.
Founding Date	Founding Date 2004	Founding Date 1994	Founding Date 2010	Founding Date N/A	Founding Date 1997
Type	Type Private	Type Public	Type Private	Type Private	Type Public
Tags	Tags Healthcare cosmetics distribution drug development pharma	Tags Healthcare cosmetics drug development pharma	Tags Healthcare cosmetics drug development pharma	Tags Healthcare cosmetics drug development pharma	Tags Healthcare cosmetics distribution drug development pharma
Locations	Locations HQ	Locations Toyonaka, JP HQ	Locations Area de Promoción El Triángulo, AR HQ	Locations San Jose, US HQ Qingdao, CN	Locations HQ
Employees	Employees N/A	Employees 90	Employees 922% increase	Employees 19	Employees N/A
Valuation ($)	Valuation ($) N/A	Valuation ($) 23.3 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 3.9 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) ¥4.8b (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥6.1b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods ¥2.4b (FY, 2025)	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥1.3b (FY, 2025)
Gross profit	Gross profit N/A	Gross profit ¥2.4b (FY, 2025)	Gross profit N/A	Gross profit N/A	Gross profit ¥4.8b (FY, 2025)
Net income	Net income N/A	Net income (¥211.4m) (FY, 2025)	Net income N/A	Net income N/A	Net income ¥1.8b (FY, 2025)